South Korea Liver Diseases Therapeutics Market Report 2022 to 2030

South Korea Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the South Korea Liver Disease Therapeutics market will reach a value of $567 Mn from $337 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030. Liver Disease Therapeutics in South Korea is dominated by a few domestic pharmaceutical companies such as Bukwang Pharm, Dong-A ST, and LISCure Biosciences. The Liver Disease Therapeutics market in South Korea is segmented into different types of disease and different therapy types. Some of the major factors affecting the South Korea Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10KRPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: South Korea AUTHOR: Dr. Vishwa Modhia

Buy Now

South Korea Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the South Korea Liver Disease Therapeutics market will reach a value of $567 Mn from $337 Mn in 2022, growing at a CAGR of 6.7% during 2022-2030.

South Korea is a high-income, developed country in Eastern Asia occupying the southern half of the Korean Peninsula. Korea was previously thought to be an area of moderate hepatitis B endemicity, with a prevalence of between 2% and 7%. The government and academic societies have made significant efforts to reduce this prevalence through nationwide screening and hepatitis B virus (HBV) vaccination and immunisation. Between 2019 and 2030, NAFLD-related decompensated cirrhosis, liver cancer diagnoses, and yearly mortality in Korea are expected to rise by 85 %, 80 %, and 90 %, respectively.

According to the latest WHO data published in 2020 Liver Disease Deaths in South Korea reached 6,348 or 2.53% of total deaths. The age-adjusted Death Rate is 7.50 per 100,000 population ranks South Korea 148^th in the world. South Korea's government spent 8.4% of its GDP on healthcare in 2020.

South Korea Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Obesity has been on the rise in recent years, owing to sedentary lifestyles and overnutrition. As a result, the prevalence of NAFLD has been steadily increasing and has become a major public health concern. Chronic hepatitis B is responsible for around 60%-80% of all liver cancer and cirrhosis incidences in South Korea (hereinafter Korea), while chronic hepatitis C is responsible for 10%-20%. South Korea, being a developed country, has significant commercial and state R&D spending, as well as a diverse industrial base. These aspects could boost the South Korea Liver Disease Therapeutics market.

Market Restraints

Many Korean patients infected with viral hepatitis do not seek treatment because they are unaware of the disease's severity or infection status. According to national surveys, a significant majority of respondents had never tested for/were unaware of their HBV (45%) or HCV (90%) infection status, or had misconceptions about viral hepatitis transmission mechanisms. While there are many hospitals in South Korea that provide liver treatment and surgery, people in remote locations may have restricted access to specialised medical facilities. South Korea has a high proportion of youth unemployment, and the country's proximity to North Korea makes doing business challenging. These factors may deter new entrants into the South Korea Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Dong-A ST: Dong-A ST is a South Korean pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B and C, and liver cirrhosis
Hanmi Pharm: Hanmi Pharm is a South Korean pharmaceutical company that develops and produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
Chong Kun Dang: Chong Kun Dang is a South Korean pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
Bukwang Pharm: Bukwang Pharm is a South Korean pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and liver cirrhosis
Green Cross
LISCure Biosciences

Recent Notable Updates

October 2022: LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on cutting-edge technologies, announced that a new drug candidate for NASH has been chosen for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2022, which will be held in November in Washington, DC. LISCure will be the first Korean biotech business to be accepted for an oral presentation at the AASLD Liver Meeting as part of the presentation. The new LISCure medication, a clinical-stage unique strain candidate, aspires to be the "first-in-class" microbiome-based therapy for NASH and other liver diseases.

Healthcare Policies and Reimbursement Scenarios

In South Korea, the Ministry of Food and Drug Safety (MFDS) is responsible for regulating the approval of drugs, including those used for liver disease treatment. The MFDS follows a strict regulatory framework that ensures the safety and efficacy of drugs. The South Korean government provides reimbursement for some liver disease treatments, including hepatitis B and C. The reimbursement is available through the country's national healthcare insurance scheme, which covers most of the population.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.